LEN vs MIST · rev $34.19B vs $160.6M cap
LEN (LEN) versus Milestone Pharmaceuticals Inc (MIST) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Milestone Pharmaceuticals Inc (MIST) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
MIST does not have a complete income-statement cache yet.
LEN currently screens at market cap $0. MIST currently screens at market cap $160.6M.
Not investment advice. Open the LEN and MIST stock pages for the full models.
Not investment advice.